Free Trial

Longboard Pharmaceuticals Q4 2023 Earnings Report

Longboard Pharmaceuticals logo
$59.98 +0.02 (+0.03%)
(As of 12/2/2024)

Longboard Pharmaceuticals EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Longboard Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Longboard Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Longboard Pharmaceuticals Earnings Headlines

H. Lundbeck A/S (HLUN-A.CO)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Longboard Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longboard Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longboard Pharmaceuticals and other key companies, straight to your email.

About Longboard Pharmaceuticals

Longboard Pharmaceuticals (NASDAQ:LBPH), a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

View Longboard Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings